Posted inInfectious Diseases Internal Medicine news
Subcutaneous Lidocaine-HP-β-CD: A Potential Disease-Modifying Breakthrough for Post-COVID Condition
A 36-week observational study demonstrates that subcutaneous lidocaine-HP-β-CD significantly improves physical and mental quality of life and reduces symptom burden in patients with post-COVID condition, offering a scalable, home-based therapeutic option for a currently underserved patient population.